飛揚集團(01901.HK):與視奕訂戰略投資合作框架協議
飛揚集團(01901.HK)表示,注意到若干網上媒體報道集團與視奕之間的業務合作。董事會澄清公司於2月10日作出的公告所披露公司與視奕於同日訂立的戰略投資合作框架協議的性質為不具法律約束力,旨在為後續展開具體合作做框架指引,有效期僅為框架協議日期起180日。
飛揚集團指,目前雙方概無就框架協議項下合作事宜進行任何磋商、協議或安排;視奕及其最終實益擁有人概無成為公司股東以作為框架協議的一部分。而公司或其附屬公司並非視奕或其任何附屬公司的股東﹐公司與視奕的業務及財務運作互相獨立,概無關聯。除框架協議外,雙方無就其他合作事宜進行任何磋商、協議或安排。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.